Skip to main content

Advertisement

Log in

Comprehensive risk management for the prevention of cerebro-cardiovascular diseases in Japan

Clinical and Experimental Nephrology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

References

  1. Japanese Society of Nephrology: evidence-based practice guideline for the treatment for CKD in Japan 2013. Tokyo Igakusha. Tokyo.

  2. Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT. Association of estimated glomerular filtration rate and albuminuria with: all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375:2073–81.

    Article  Google Scholar 

  3. Iso H, Date C, Yamamoto A, Toyoshima H, Watanabe Y, Kikuchi S, Koizumi A, Wada Y, Kondo T, Inaba Y, Tamakoshi A, the JACC Study Group. Smoking cessation and mortality from cardiovascular disease among Japanese men and women: the JACC Study. Am J Epidemiol. 2005;161:170–9.

    Article  PubMed  Google Scholar 

  4. Suskin N, Sheth T, Negassa A, Yusuf S. Relationship of current and past smoking to mortality and morbidity in patient with left ventricular dysfunction. J Am Coll Cardiol. 2001;37:1677–82.

    Article  CAS  PubMed  Google Scholar 

  5. Yoshiike N, et al. J Japan Soc Study Obes. 2000;6:4–17.

    Google Scholar 

  6. Suzuki R, Watanabe S, Hirai Y, Akiyama K, Nishide T, Matsushima Y, Murayama H, Ohshima H, Shinomiya M, Shirai K, Saito Y, Yoshida S, Saisho H, Ohto M. Abdominal wall fat index, estimated by ultrasonography, for assessment of ratio of visceral fat to subcutaneous fat in the abdomen. Am J Med. 1993;95:309–14.

    Article  CAS  PubMed  Google Scholar 

  7. Evidence-based Practice Guideline for the Treatment for Diabetes in Japan 2013.

  8. Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012.

  9. Committee on Diagnostic Criteria for Metabolic Syndrome. Definition and diagnostic criteria of metabolic syndrome. J Jpn Soc Intern Med. 2005; 94: 794–809.

Download references

Author information

Authors and Affiliations

Consortia

Ethics declarations

Conflict of interest

Tamio Teramoto: Honoraria; Astellas Pharma Inc., Kowa Pharmaceutical Company Ltd., Daiichi Sankyo Company, Limited, Takeda Pharmaceutical Company Limited, Bayer Yakuhin, Ltd., Pfizer Japan Inc. Research funding; ASKA Pharmaceutical. Co., Ltd., Kissei Pharmaceutical Co., Ltd., Kowa Pharmaceutical Company Ltd., Bayer Yakuhin, Ltd., Mochida Pharmaceutical Co., Ltd. Masayuki Yokde: Research funding; Otsuka Pharmaceutical Co., Ltd. Donation; Daiichi Sankyo Company, Limited. Tsuyoshi Kimura: Honoraria; Astellas Pharma Inc., AstraZeneca K.K., Abbott Vascular Japan Co., Ltd., MSD K.K, Kowa Pharmaceutical Company Ltd., Sanofi K.K., Daiichi Sankyo Company, Limited, Pfizer Japan Inc. Research funding; Daiichi Sankyo Company, Limited, Toray Medical Co., Ltd., Heart Flow. Donation; Abbott Vascular Japan Co., Ltd., MSD K.K, Sanofi K.K., Daiichi Sankyo Company, Limited, Takeda Pharmaceutical Company Limited, Novartis Pharma K.K. Masayasu Matsumoto: Honoraria; Eisai Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Sanofi K.K., Daiichi Sankyo Company, Limited, Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Company Limited, Nippon Boehringer Ingelheim Co., Ltd., Bayer Yakuhin, Ltd., Mochida Pharmaceutical Co., Ltd. Donation; Otsuka Pharmaceutical Co., Ltd., Sanofi K.K., Daiichi Sankyo Company, Limited, Takeda Pharmaceutical Company Limited, Nippon Boehringer Ingelheim Co., Ltd., Mochida Pharmaceutical Co., Ltd. Hidenori Arai: Employment/Leadership position/Advisory role; Possible Medical Science. Honoraria; MSD K.K., Kowa Pharmaceutical Company Ltd., Daiichi Sankyo Company, Limited. Donation; Otsuka Pharmaceutical Co., Ltd., Daiichi Sankyo Company, Limited. Hiromi Rakugi: Honoraria; Astellas Pharma Inc., MSD K.K., Kyowa Hakko Kirin Co., Ltd., Shionogi & Co., Ltd., Daiichi Sankyo Company, Limited, Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Company Limited, Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma K.K., Pfizer Japan Inc. Mochida Pharmaceutical Co., Ltd. Honoraria; MSD K.K., Yowa Hakko Kirin Co., Ltd. Research funding; Novartis Pharma K.K. Donation; Astellas Pharma Inc., MSD K.K., Kyowa Hakko Kirin Co., Ltd., Shionogi & Co., Ltd. Daiichi Sankyo Company, Limited, Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Company Limited, Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma K.K., Pfizer Japan Inc. Hirohito Sone: Honoraria; Astellas Pharma Inc., Ono Pharmaceutical Co., Ltd., Kowa Pharmaceutical Company Ltd., Sanofi K.K., Sanwa Kagaku Kenkyusho Co., Ltd., Daiichi Sankyo Company, Limited, Mitsubishi Tanabe Pharma Corporation, Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma K.K., Novo Nordisk Pharma Ltd. Research funding; Novo Nordisk Pharma Ltd. Donation; Asahi Kasei Pharma Corporation, Astellas Pharma Inc., Eisai Co., Ltd., MSD K.K., Otsuka Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Sanofi K.K., Daiichi Sankyo Company, Limited, Taisho Toyama Pharmaceutical Co., Ltd. Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Company Limited, Mitsubishi Tanabe Pharma Corporation, Eli Lilly Japan K.K., Japan Blood Products Organization, Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma K.K., Pfizer Japan Inc., Meiji Seika Pharma Co., Ltd., Yakult Honsha Co., Ltd. Shizuya Yamashita: Honoraria; MSD K.K., Kowa Company, Ltd., Kowa Pharmaceutical Company Ltd., Sanwa Kagaku Kenkyusho Co., Ltd., Takeda Pharmaceutical Company Limited, Bayer Yakuhin, Ltd. Research funding; National Institute of Biomedical Innovation, Otsuka Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Kyowa Medex Co., Ltd., Kowa Pharmaceutical Company Ltd., Sanwa Kagaku Kenkyusho Co., Ltd., Shionogi & Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Bayer Yakuhin, Ltd. Donation; Astellas Pharma Inc., AstraZeneca K.K., MSD K.K., Sanwa Kagaku Kenkyusho Co., Ltd., Daiichi Sankyo Company, Limited, Takeda Pharmaceutical Company Limited., Mochida Pharmaceutical Co., Ltd.

Participating societies and organizations

The Japanese Society of Internal Medicine, the Japan Epidemiological Association, the Japanese Society of Hypertension, the Japanese Circulation Society, the Japanese Society of Nephrology, the Japanese Society of Physical Fitness and Sports Medicine, the Japan Diabetes Society, the Japan Atherosclerosis Society, the Japan Stroke Society, the Japan Society for the Study of Obesity, the Japan Geriatrics Society, the Japanese Association of Medical Sciences, and the Japan Medical Association.

Writing committee

Tamio Teramoto, Masayuki Yokode, Hiroyasu Iso, Akihiko Kitamura, Hiroki Shiomi, Tsuyoshi Kimura, Masayasu Matsumoto, Mami Iida, Jun Sasaki, Shigeru Inoue, Ryouichi Nagatomi, Tetsuo Shoji, Hidenori Arai, Hiromi Rakugi, Hirohito Sone, Shizuya Yamashita, Shigeru Mizyzaki.

Additional information

This is the English version of “Comprehensive risk management for the prevention of cerebro-cardiovascular diseases in Japan”, published in Japanese in April 2015.

This article, copublished in the Journal of Epidemiology, is published on behalf of the Japan Epidemiological Association, Hypertension Research on behalf of the Japanese Society of Hypertension, Circulation Journal on behalf of the Japanese Circulation Society, Clinical and Experimental Nephrology on behalf of Japanese Society of Nephrology, the Journal of Physical Fitness and Sports Medicine on behalf of the Japanese Society of Physical Fitness and Sports Medicine, Diabetology  International on behalf of the Japan Diabetes Society, Journal of Atherosclerosis and Thrombosis on behalf of the Japan Atherosclerosis Society, Journal of Japan Society for the Study of Obesity on behalf of the Japan Society for the Study of Obesity, and Geriatrics & Gerontology International on behalf of the Japan Geriatrics Society.

The committee consisted of representatives from the following organizations: the Japan Epidemiological Association, the Japanese Society of Hypertension, the Japanese Circulation Society, Japanese Society of Nephrology, the Japanese Society of Physical Fitness and Sports Medicine, the Japan Diabetes Society, the Japan Atherosclerosis Society, the Japan Society for the Study of Obesity, and the Japan Geriatrics Society.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PDF 4081 kb)

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Joint Committee for Comprehensive Risk Management Chart for the Prevention of Cerebro-Cardiovascular Diseases. Comprehensive risk management for the prevention of cerebro-cardiovascular diseases in Japan. Clin Exp Nephrol 21, 743–754 (2017). https://doi.org/10.1007/s10157-017-1456-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10157-017-1456-z

Navigation